Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04045795 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: isatuximab SAR650984 IV
DRUG: pomalidomide
DRUG: dexamethasone
DRUG: isatuximab SAR650984 SC
DEVICE: Investigational injector device

Sponsor

Sanofi